VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35152220/
Tumors induce angiogenesis to acquire oxygen and nutrition from their adjacent microenvironment. Tumor angiogenesis has been believed to be induced primarily by the secretion of vascular endothelial growth factor-A (VEGF-A)...
Relevance/Conclusion:Various molecular targeting drugs are currently being evaluated as potential antitumor therapies. We expect that precision medicine will permit the development of innovative antiangiogenic therapies targeting individual angiogenic factors selected on the basis of the genetic screening of tumors.
Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
Source : https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.14346
You-Kuang Kang , Fan-Chun Meng , Corresponding Author Fan-Chun Meng Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan...
Conclusion/Relevance: This is the first report of mortality due to osimertinib-related acute fulminant hepatitis. Clinicians should routinely arrange for hepatitis B virus (HBV) screening and prescribe antiviral drugs to patients with chronic HBV infection before osimertinib administration.
Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer
Source : https://www.futuremedicine.com/doi/10.2217/fon-2021-1452
Aim: Assess factors associated with EGFR TKI initiation among patients with metastatic non-small-cell lung cancer (mNSCLC). Patients & methods: Medicare Part D patients diagnosed with non-squamous mNSCLC and starting an...
Conclusion: Patient demographics and clinical characteristics may affect timeliness of EGFR TKI treatment for mNSCLC. Future research should examine potential barriers to treatment.
A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer
Source : https://cancerres.aacrjournals.org/content/early/2022/02/11/0008-5472.CAN-21-2693
In-frame insertions in exon 20 of human epidermal growth factor receptor-2 (HER2) are the most common HER2 mutations in non-small cell lung cancer (NSCLC) patients, a disease in which approved...
Conclusion/Relevance: Taken together, the dual activity of JBJ-08-178-01 as a selective inhibitor and destabilizer of HER2 represents a combination which may lead to better efficacy and tolerance in NSCLC patients harboring HER2 genetic alterations or amplification.
Effect of education and standardization of cardiac dose constraints on heart dose in lung cancer patients receiving definitive radiation therapy across a statewide consortium
Source : https://www.practicalradonc.org/article/S1879-8500(22)00007-8/fulltext
Purpose/Objectives: Cardiac radiation exposure is associated with an increased rate of adverse cardiac events in patients receiving radiation therapy for locally advanced non-small cell lung carcinoma (NSCLC). Previous analysis of...
Conclusions: Education and implementation of a standardized cardiac dose quality measure across a statewide consortium was associated with a reduction of mean heart dose in patients receiving radiation therapy for locally advanced NSCLC. These dose reductions were achieved without sacrificing target coverage, increasing mean lung dose, or...